​

CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

OverviewForecastRevenueFinancialsChart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 69.72% institutional investors, 1.71% insiders, and 28.57% retail investors. Capital investors is the largest institutional shareholder, holding 9.62% of CRSP shares. ARK Innovation ETF is the top mutual fund, with 6.41% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCRISPR Therapeutics69.72%1.71%28.57%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Capital investors7.87M9.62%$424.80M
Ark investment management7.78M9.51%$420.12M
Nikko asset management americas3.15M3.85%$169.99M
Sumitomo mitsui trust3.15M3.85%$170.21M
Blackrock2.78M3.40%$150.03M
T. rowe price investment management2.73M3.34%$147.48M
State street2.39M2.93%$129.28M
Fmr2.35M2.88%$127.09M
Vanguard group1.75M2.14%$94.44M
Nea management company1.59M1.94%$85.76M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management498.56K34.84%$26.93M
Sr one capital management, lp1.05M17.74%$56.65M
Nea management company1.59M6.45%$85.76M
Spear rsc165.00K6.29%$8.91M
Ark investment management7.78M3.73%$420.12M
Contrarius investment management685.72K2.32%$37.04M
Ecor1 capital1.39M2.30%$75.03M
Nikko asset management americas3.15M1.96%$169.99M
Eagle health investments lp197.00K1.87%$10.64M
Tang capital management316.50K1.74%$17.09M

Top Buyers

HolderShares% AssetsChange
State street2.39M0.01%898.48K
Norges bank650.21K0.01%650.21K
Ubs asset management americas693.96K0.01%583.49K
Blackrock2.78M0.00%231.42K
Tang capital management316.50K1.74%200.00K

Top Sellers

HolderShares% AssetsChange
Farallon capital management---530.00K
Morgan stanley597.68K0.00%-488.25K
Avoro capital advisors---419.58K
Ark investment management7.78M3.73%-378.49K
Cutter capital management, lp---201.50K

New Positions

HolderShares% AssetsChangeValue
Norges bank650.21K0.01%650.21K$35.12M
Baker bros. advisors lp100.00K0.07%100.00K$5.40M
Balyasny asset management90.66K0.01%90.66K$4.90M
Mirae asset global etfs77.02K0.01%77.02K$4.17M
Lmr partners llp28.60K0.01%28.60K$1.54M

Sold Out

HolderChange
Impact partnership wealth-1.00
Mv capital management-3.00
Assetmark-4.00
Toronto dominion bank-4.00
Baldwin brothers llc/ma-4.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024437-9.15%59,424,788-0.24%691.31%167-19.71%1311.55%
Jun 30, 2024478-7.54%59,547,6001.78%721.42%205-12.02%129-9.15%
Mar 31, 20245170.58%58,507,2425.59%711.48%233-10.73%14215.45%
Dec 31, 202351417.62%55,408,0780.82%691.45%26131.16%12314.95%
Sep 30, 2023437-3.32%54,958,2020.44%691.45%19919.16%107-21.32%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Innovation ETF5.46M6.41%-
ARK Disruptive Innovation Full Composite5.18M6.09%-266.51K
American Funds New Perspective A4.69M5.51%-
Capital Group New Perspective Comp4.69M5.51%-
SPDR® S&P Biotech ETF2.36M2.77%26.14K
ARK Genomic Revolution ETF1.82M2.14%8.76K
ARK Genomic Revolution1.76M2.07%7.52K
Nikko AM ARK Disruptive Innovation A USD1.44M1.69%-28.30K
Nikko AM ARK Pstv Chg Innovt P JPY Acc1.30M1.52%-29.36K
Vanguard Institutional Extnd Mkt Idx Tr1.27M1.49%-4.66K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 02, 2024Kulkarni Samarth Chief Executive OfficerSell$826.56K
Nov 11, 2024Kulkarni Samarth Chief Executive OfficerSell$1.28M
Nov 11, 2024Kulkarni Samarth Chief Executive OfficerSell$387.08K
Oct 14, 2024KASINGER JAMES R. General Counsel and SecretarySell$50.40K
Oct 14, 2024Kulkarni Samarth Chief Executive OfficerSell$198.68K

Insider Transactions Trends

DateBuySell
2024 Q4-5
2024 Q3--
2024 Q2-3
2024 Q1-15
2023 Q4--

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 69.72%, followed by 1.71% insiders and 28.57% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 47.04%, which CRISPR Therapeutics exceeds.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Capital investors (7.87M shares, 9.62%), Ark investment management (7.78M shares, 9.51%), and Nikko asset management americas (3.15M shares, 3.85%). Together, they hold 22.98% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 34.84% of its assets in 498.56K CRISPR Therapeutics shares, valued at 26.93M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Innovation ETF is the top mutual fund holder of CRISPR Therapeutics shares, with 6.41% of its total shares outstanding invested in 5.46M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools